BERLIN — German pharmaceutical company CureVac says it has signed a contract to produce major quantities of a COVID-19 vaccine under development in the Netherlands.
The Tuebingen company said Monday it had agreed with Munich’s Wacker Chemie AG on a contract for the production of its COVID-19 vaccine using mRNA technology at Wacker’s site in Amsterdam in the first half of 2021.
It plans to produce 100 million doses of the CureVac vaccine per year at the facility, and said there is potential for expansion.
CureVac says the vaccine it is developing can be stored at regular refrigerator temperatures for up to three months, and even unrefrigerated at regular room temperatures for a period of 24 hours.
CureVac isn’t as far along in its trials, however, and says it plans to initiate a phase 2b/3 clinical study before year’s end.
The European Commission last week said it has sealed an agreement to buy up to 405 million doses of CureVac’s product as part of its procurement of the vaccine from various sources.
Germany’s state-owned KfW bank owns a 23% stake in CureVac.